Zealand Pharma to Showcase Petrelintide Phase 2 Data at ADA 2026
Event summary
- Zealand Pharma will present Phase 2 ZUPREME-1 trial data on petrelintide at the ADA 2026 Scientific Sessions, June 5–8.
- Late-breaking data on the amylin analog will be featured in ePoster Theater and poster sessions.
- ZUPREME-1 enrolled 493 participants across 32 sites in the U.S., Poland, and Romania.
- Petrelintide is being developed in collaboration with Roche for obesity and metabolic health.
The big picture
Zealand Pharma's presentation at ADA 2026 underscores the growing focus on amylin-based therapies for obesity, a market increasingly dominated by GLP-1 agonists. The collaboration with Roche adds strategic weight, suggesting potential for broader commercialization. The Phase 2 data could position petrelintide as a next-generation treatment if efficacy and safety profiles meet or exceed current standards.
What we're watching
- Clinical Efficacy
- How petrelintide's Phase 2 results compare to existing obesity treatments in terms of weight loss and safety.
- Regulatory Pathway
- Whether the ADA data accelerates petrelintide's development timeline toward Phase 3 trials.
- Market Positioning
- The pace at which Zealand Pharma can differentiate petrelintide in a competitive obesity drug landscape.
Related topics